Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | IDH2 | P48735 | 5/20 | 0.45 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.43 |
| ▸ | MAT2A | P31153 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21889142 | 0.86 | ALDH1A1 (0.39) | MAPK1NOS2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL3809824 | 0.83 | IL1B (0.47) | MAPK1NOS3NOS2ALDH1A1GAA | |
| SCHEMBL1443173 | 0.82 | MAPK1 (0.51) | MAPK1NOS3NOS2ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL14744005 | 0.81 | ALDH1A1 (0.52) | MAPK1NOS3NOS2ALDH1A1GAA | |
| SCHEMBL23837624 | 0.79 | NOS3 (0.49) | MAPK1NOS3NOS2ALDH1A1GAA | |
| SCHEMBL17923119 | 0.79 | ALDH1A1 (0.51) | MAPK1NOS3NOS2ALDH1A1GAA | |
| SCHEMBL31294545 | 0.79 | IL1B (0.43) | IDH2RIOK2PHGDH | |
| SCHEMBL24605491 | 0.79 | MEN1 (0.41) | NOS2ALDH1A1RIOK2SYK | |
| SCHEMBL17700752 | 0.79 | NOS2 (0.54) | NOS2ALDH1A1L3MBTL1PHGDH | |
| SCHEMBL26686808 | 0.79 | IRAK4 (0.35) | NOS2IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3031799-B1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9776962-B2 | Aromatic compounds with GPR40 agonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| EP-3031799-A1 | AROMATIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-20160115128-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115128-A1 | AROMATIC COMPOUND | GLP1R, GPR119, GPR39 | MAPK1 216/4885NOS3 3207/4885NOS2 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.